Annual EBITDA
$1.39 B
+$352.50 M+34.08%
31 December 2023
Summary:
United Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently $1.39 billion, with the most recent change of +$352.50 million (+34.08%) on 31 December 2023. During the last 3 years, it has risen by +$674.50 million (+94.69%). UTHR annual EBITDA is now at all-time high.UTHR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$417.80 M
+$32.20 M+8.35%
30 September 2024
Summary:
United Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently $417.80 million, with the most recent change of +$32.20 million (+8.35%) on 30 September 2024. Over the past year, it has increased by +$37.10 million (+9.75%). UTHR quarterly EBITDA is now -43.99% below its all-time high of $745.90 million, reached on 30 September 2015.UTHR Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$1.55 B
+$37.10 M+2.44%
30 September 2024
Summary:
United Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently $1.55 billion, with the most recent change of +$37.10 million (+2.44%) on 30 September 2024. Over the past year, it has increased by +$287.60 million (+22.70%). UTHR TTM EBITDA is now -1.41% below its all-time high of $1.58 billion, reached on 30 June 2016.UTHR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
UTHR EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +34.1% | +9.8% | +22.7% |
| 3 y3 years | +94.7% | +88.7% | +144.1% |
| 5 y5 years | +71.5% | +118.4% | +2734.8% |
UTHR EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +109.4% | -2.1% | +164.8% | at high | +144.1% |
| 5 y | 5 years | at high | +1951.5% | -2.1% | +742.3% | at high | +2175.4% |
| alltime | all time | at high | +1799.9% | -44.0% | +166.3% | -1.4% | +1204.0% |
United Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $417.80 M(+8.4%) | $1.55 B(+2.4%) |
| June 2024 | - | $385.60 M(-9.7%) | $1.52 B(+1.5%) |
| Mar 2024 | - | $426.90 M(+31.7%) | $1.49 B(+7.8%) |
| Dec 2023 | $1.39 B(+34.1%) | $324.20 M(-14.8%) | $1.39 B(+9.5%) |
| Sept 2023 | - | $380.70 M(+4.9%) | $1.27 B(+3.8%) |
| June 2023 | - | $362.90 M(+13.8%) | $1.22 B(+18.8%) |
| Mar 2023 | - | $319.00 M(+56.1%) | $1.03 B(-0.7%) |
| Dec 2022 | $1.03 B(+56.1%) | $204.30 M(-38.9%) | $1.03 B(+4.7%) |
| Sept 2022 | - | $334.60 M(+97.4%) | $987.80 M(+12.9%) |
| June 2022 | - | $169.50 M(-48.0%) | $874.60 M(-6.8%) |
| Mar 2022 | - | $325.90 M(+106.5%) | $938.70 M(+41.7%) |
| Dec 2021 | $662.40 M(-7.0%) | $157.80 M(-28.7%) | $662.40 M(+4.0%) |
| Sept 2021 | - | $221.40 M(-5.2%) | $636.90 M(-2.2%) |
| June 2021 | - | $233.60 M(+371.0%) | $651.20 M(+14.3%) |
| Mar 2021 | - | $49.60 M(-62.5%) | $569.70 M(-20.0%) |
| Dec 2020 | $712.30 M(-1051.0%) | $132.30 M(-43.9%) | $712.30 M(+6.2%) |
| Sept 2020 | - | $235.70 M(+55.0%) | $670.80 M(+7.1%) |
| June 2020 | - | $152.10 M(-20.9%) | $626.40 M(-16.2%) |
| Mar 2020 | - | $192.20 M(+111.7%) | $747.30 M(-1097.7%) |
| Dec 2019 | -$74.90 M(-109.3%) | $90.80 M(-52.5%) | -$74.90 M(+26.9%) |
| Sept 2019 | - | $191.30 M(-29.9%) | -$59.00 M(-39.0%) |
| June 2019 | - | $273.00 M(-143.3%) | -$96.70 M(-31.3%) |
| Mar 2019 | - | -$630.00 M(-690.4%) | -$140.80 M(-117.4%) |
| Dec 2018 | $808.70 M(-0.1%) | $106.70 M(-30.5%) | $808.70 M(-5.3%) |
| Sept 2018 | - | $153.60 M(-32.9%) | $854.20 M(-17.3%) |
| June 2018 | - | $228.90 M(-28.4%) | $1.03 B(+20.5%) |
| Mar 2018 | - | $319.50 M(+109.9%) | $856.70 M(+5.8%) |
| Dec 2017 | $809.50 M(-26.1%) | $152.20 M(-54.1%) | $809.50 M(-3.5%) |
| Sept 2017 | - | $331.70 M(+522.3%) | $838.80 M(+11.1%) |
| June 2017 | - | $53.30 M(-80.4%) | $754.90 M(-24.2%) |
| Mar 2017 | - | $272.30 M(+50.0%) | $995.80 M(-9.1%) |
| Dec 2016 | $1.10 B(+1.3%) | $181.50 M(-26.8%) | $1.10 B(+1.6%) |
| Sept 2016 | - | $247.80 M(-15.8%) | $1.08 B(-31.6%) |
| June 2016 | - | $294.20 M(-21.0%) | $1.58 B(+7.9%) |
| Mar 2016 | - | $372.20 M(+126.4%) | $1.46 B(+35.0%) |
| Dec 2015 | $1.08 B(+88.2%) | $164.40 M(-78.0%) | $1.08 B(-2.1%) |
| Sept 2015 | - | $745.90 M(+318.8%) | $1.10 B(+228.9%) |
| June 2015 | - | $178.10 M(-2882.8%) | $335.89 M(-2.1%) |
| Mar 2015 | - | -$6.40 M(-103.4%) | $343.21 M(-40.3%) |
| Dec 2014 | $575.00 M(+75.2%) | $187.21 M(-913.3%) | $575.00 M(+56.0%) |
| Sept 2014 | - | -$23.02 M(-112.4%) | $368.48 M(-27.0%) |
| June 2014 | - | $185.42 M(-17.7%) | $504.88 M(+12.2%) |
| Mar 2014 | - | $225.39 M(-1266.9%) | $450.18 M(+37.2%) |
| Dec 2013 | $328.22 M(-32.2%) | -$19.32 M(-117.0%) | $328.22 M(-32.2%) |
| Sept 2013 | - | $113.38 M(-13.3%) | $484.27 M(-1.3%) |
| June 2013 | - | $130.72 M(+26.4%) | $490.68 M(+3.6%) |
| Mar 2013 | - | $103.44 M(-24.4%) | $473.42 M(-2.3%) |
| Dec 2012 | $484.45 M(+42.1%) | $136.73 M(+14.1%) | $484.45 M(+16.0%) |
| Sept 2012 | - | $119.79 M(+5.6%) | $417.72 M(+2.7%) |
| June 2012 | - | $113.46 M(-0.9%) | $406.59 M(-1.6%) |
| Mar 2012 | - | $114.47 M(+63.5%) | $413.01 M(+20.8%) |
| Dec 2011 | $341.02 M | $70.00 M(-35.6%) | $341.83 M(+17.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2011 | - | $108.66 M(-9.4%) | $291.81 M(+16.1%) |
| June 2011 | - | $119.88 M(+177.0%) | $251.33 M(+26.9%) |
| Mar 2011 | - | $43.28 M(+116.6%) | $198.10 M(+2.8%) |
| Dec 2010 | $192.78 M(+348.0%) | $19.98 M(-70.7%) | $192.76 M(+9.3%) |
| Sept 2010 | - | $68.18 M(+2.3%) | $176.42 M(+43.3%) |
| June 2010 | - | $66.65 M(+75.7%) | $123.12 M(+117.6%) |
| Mar 2010 | - | $37.94 M(+940.3%) | $56.58 M(+31.5%) |
| Dec 2009 | $43.04 M(-163.5%) | $3.65 M(-75.5%) | $43.03 M(-146.8%) |
| Sept 2009 | - | $14.88 M(>+9900.0%) | -$91.91 M(+8.2%) |
| June 2009 | - | $108.00 K(-99.6%) | -$84.91 M(+28.6%) |
| Mar 2009 | - | $24.40 M(-118.6%) | -$66.03 M(-11.3%) |
| Dec 2008 | -$67.75 M(-405.4%) | -$131.30 M(-700.0%) | -$74.44 M(-214.6%) |
| Sept 2008 | - | $21.88 M(+15.2%) | $64.98 M(+13.5%) |
| June 2008 | - | $18.99 M(+18.8%) | $57.26 M(+22.9%) |
| Mar 2008 | - | $15.98 M(+96.7%) | $46.57 M(+100.3%) |
| Dec 2007 | $22.18 M(-27.1%) | $8.13 M(-42.6%) | $23.25 M(+24.4%) |
| Sept 2007 | - | $14.16 M(+70.5%) | $18.70 M(+14.2%) |
| June 2007 | - | $8.30 M(-213.2%) | $16.38 M(-18.5%) |
| Mar 2007 | - | -$7.33 M(-305.3%) | $20.09 M(-34.0%) |
| Dec 2006 | $30.45 M(-32.8%) | $3.57 M(-69.8%) | $30.45 M(-19.6%) |
| Sept 2006 | - | $11.83 M(-1.5%) | $37.85 M(-8.0%) |
| June 2006 | - | $12.02 M(+297.8%) | $41.14 M(+0.6%) |
| Mar 2006 | - | $3.02 M(-72.5%) | $40.90 M(-9.7%) |
| Dec 2005 | $45.31 M(+192.6%) | $10.97 M(-27.5%) | $45.31 M(+9.8%) |
| Sept 2005 | - | $15.13 M(+28.4%) | $41.26 M(+27.3%) |
| June 2005 | - | $11.78 M(+58.5%) | $32.41 M(+31.2%) |
| Mar 2005 | - | $7.43 M(+7.2%) | $24.70 M(+59.5%) |
| Dec 2004 | $15.48 M(-268.3%) | $6.93 M(+10.4%) | $15.49 M(+172.9%) |
| Sept 2004 | - | $6.27 M(+54.1%) | $5.67 M(-419.8%) |
| June 2004 | - | $4.07 M(-327.6%) | -$1.77 M(-78.0%) |
| Mar 2004 | - | -$1.79 M(-37.9%) | -$8.08 M(-12.2%) |
| Dec 2003 | -$9.20 M(-38.1%) | -$2.88 M(+145.6%) | -$9.20 M(+2.9%) |
| Sept 2003 | - | -$1.17 M(-47.4%) | -$8.94 M(-34.9%) |
| June 2003 | - | -$2.23 M(-23.5%) | -$13.74 M(+16.1%) |
| Mar 2003 | - | -$2.91 M(+11.1%) | -$11.83 M(-20.4%) |
| Dec 2002 | -$14.87 M(-65.8%) | -$2.62 M(-56.1%) | -$14.87 M(-27.0%) |
| Sept 2002 | - | -$5.97 M(+1736.9%) | -$20.36 M(-20.0%) |
| June 2002 | - | -$325.00 K(-94.5%) | -$25.45 M(-31.9%) |
| Mar 2002 | - | -$5.95 M(-26.6%) | -$37.34 M(-12.4%) |
| Dec 2001 | -$43.42 M(-46.8%) | -$8.11 M(-26.6%) | -$42.62 M(-35.0%) |
| Sept 2001 | - | -$11.06 M(-9.5%) | -$65.58 M(+1.0%) |
| June 2001 | - | -$12.22 M(+8.8%) | -$64.93 M(-22.0%) |
| Mar 2001 | - | -$11.23 M(-63.9%) | -$83.20 M(+2.0%) |
| Dec 2000 | -$81.58 M(+122.5%) | -$31.07 M(+198.5%) | -$81.58 M(+32.9%) |
| Sept 2000 | - | -$10.41 M(-65.8%) | -$61.37 M(+6.1%) |
| June 2000 | - | -$30.48 M(+217.1%) | -$57.86 M(+72.3%) |
| Mar 2000 | - | -$9.61 M(-11.5%) | -$33.58 M(-7.4%) |
| Dec 1999 | -$36.66 M(+174.7%) | -$10.86 M(+57.4%) | -$36.26 M(+42.8%) |
| Sept 1999 | - | -$6.90 M(+11.3%) | -$25.40 M(+37.3%) |
| June 1999 | - | -$6.20 M(-49.6%) | -$18.50 M(+50.4%) |
| Mar 1999 | - | -$12.30 M | -$12.30 M |
| Dec 1998 | -$13.35 M | - | - |
FAQ
- What is United Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for United Therapeutics?
- What is United Therapeutics annual EBITDA year-on-year change?
- What is United Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for United Therapeutics?
- What is United Therapeutics quarterly EBITDA year-on-year change?
- What is United Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for United Therapeutics?
- What is United Therapeutics TTM EBITDA year-on-year change?
What is United Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of UTHR is $1.39 B
What is the all time high annual EBITDA for United Therapeutics?
United Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is $1.39 B
What is United Therapeutics annual EBITDA year-on-year change?
Over the past year, UTHR annual earnings before interest, taxes, depreciation & amortization has changed by +$352.50 M (+34.08%)
What is United Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of UTHR is $417.80 M
What is the all time high quarterly EBITDA for United Therapeutics?
United Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $745.90 M
What is United Therapeutics quarterly EBITDA year-on-year change?
Over the past year, UTHR quarterly earnings before interest, taxes, depreciation & amortization has changed by +$37.10 M (+9.75%)
What is United Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of UTHR is $1.55 B
What is the all time high TTM EBITDA for United Therapeutics?
United Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $1.58 B
What is United Therapeutics TTM EBITDA year-on-year change?
Over the past year, UTHR TTM earnings before interest, taxes, depreciation & amortization has changed by +$287.60 M (+22.70%)